A newly developed uroplakin ii antibody with increased sensitivity in urothelial carcinoma of the bladder

Laura L. Hoang, David E. Tacha, Weimin Qi, Charlie Yu, Ryan E. Bremer, Joseph Chu, Thomas S. Haas, Liang Cheng

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Context.-Uroplakin II is a 15-kDa protein component of the urothelial plaques that enhance the permeability barrier and strength of the urothelium. Studies have shown uroplakin II messenger RNA to be expressed in bladder cancer tissues and peripheral blood of patients with urothelial carcinoma. Little is known about the protein expression of uroplakin II in urothelial carcinoma, possibly because of the absence of a commercially available uroplakin II antibody. Pathologists have used the uroplakin III antibody (AU1) to identify tumors of urothelial origin; however, the use of AU1 is limited because of its poor sensitivity. Objectives.-To evaluate a newly developed mouse monoclonal uroplakin II antibody (BC21) in urothelial carcinoma and to compare it with previously developed mouse monoclonal uroplakin III (BC17 and AU1). Design.-Uroplakin II and III antibodies were optimized for staining using a horseradish peroxidase-polymer detection system and were visualized with 3,30-diaminobenzidine. Results.-BC21, BC17, and AU1 demonstrated sensitivities in urothelial carcinoma of the bladder of 79% (44 of 56), 55% (31 of 56) (P = 002), and 34% (19 of 56) (P < .001), respectively. Subsequently, the increased staining sensitivity and intensity of BC21, compared with BC17, was validated in a larger study (134 of 174; 77% and 94 of 174; 54%, respectively) (P < .001). BC21 was found to be highly specific when evaluated in various normal and neoplastic tissues, including prostatic and renal carcinomas. Conclusions.-The mouse monoclonal uroplakin II antibody (BC21) demonstrated superior sensitivity and specificity in urothelial carcinoma, compared with uroplakin III (BC17 and AU1), suggesting its advantages in the differential diagnosis of urothelial carcinoma and in the detection of tumors of unknown origin.

Original languageEnglish
Pages (from-to)943-949
Number of pages7
JournalArchives of Pathology and Laboratory Medicine
Volume138
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Uroplakins
Uroplakin II
Uroplakin III
Urinary Bladder
Carcinoma
Antibodies
Staining and Labeling
Urothelium
Horseradish Peroxidase
Urinary Bladder Neoplasms
Permeability
Neoplasms
Polymers
Proteins
Differential Diagnosis
Kidney
Sensitivity and Specificity
Messenger RNA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

A newly developed uroplakin ii antibody with increased sensitivity in urothelial carcinoma of the bladder. / Hoang, Laura L.; Tacha, David E.; Qi, Weimin; Yu, Charlie; Bremer, Ryan E.; Chu, Joseph; Haas, Thomas S.; Cheng, Liang.

In: Archives of Pathology and Laboratory Medicine, Vol. 138, No. 7, 2014, p. 943-949.

Research output: Contribution to journalArticle

Hoang, Laura L. ; Tacha, David E. ; Qi, Weimin ; Yu, Charlie ; Bremer, Ryan E. ; Chu, Joseph ; Haas, Thomas S. ; Cheng, Liang. / A newly developed uroplakin ii antibody with increased sensitivity in urothelial carcinoma of the bladder. In: Archives of Pathology and Laboratory Medicine. 2014 ; Vol. 138, No. 7. pp. 943-949.
@article{8e4e304446cb430786bb09902de7c7a4,
title = "A newly developed uroplakin ii antibody with increased sensitivity in urothelial carcinoma of the bladder",
abstract = "Context.-Uroplakin II is a 15-kDa protein component of the urothelial plaques that enhance the permeability barrier and strength of the urothelium. Studies have shown uroplakin II messenger RNA to be expressed in bladder cancer tissues and peripheral blood of patients with urothelial carcinoma. Little is known about the protein expression of uroplakin II in urothelial carcinoma, possibly because of the absence of a commercially available uroplakin II antibody. Pathologists have used the uroplakin III antibody (AU1) to identify tumors of urothelial origin; however, the use of AU1 is limited because of its poor sensitivity. Objectives.-To evaluate a newly developed mouse monoclonal uroplakin II antibody (BC21) in urothelial carcinoma and to compare it with previously developed mouse monoclonal uroplakin III (BC17 and AU1). Design.-Uroplakin II and III antibodies were optimized for staining using a horseradish peroxidase-polymer detection system and were visualized with 3,30-diaminobenzidine. Results.-BC21, BC17, and AU1 demonstrated sensitivities in urothelial carcinoma of the bladder of 79{\%} (44 of 56), 55{\%} (31 of 56) (P = 002), and 34{\%} (19 of 56) (P < .001), respectively. Subsequently, the increased staining sensitivity and intensity of BC21, compared with BC17, was validated in a larger study (134 of 174; 77{\%} and 94 of 174; 54{\%}, respectively) (P < .001). BC21 was found to be highly specific when evaluated in various normal and neoplastic tissues, including prostatic and renal carcinomas. Conclusions.-The mouse monoclonal uroplakin II antibody (BC21) demonstrated superior sensitivity and specificity in urothelial carcinoma, compared with uroplakin III (BC17 and AU1), suggesting its advantages in the differential diagnosis of urothelial carcinoma and in the detection of tumors of unknown origin.",
author = "Hoang, {Laura L.} and Tacha, {David E.} and Weimin Qi and Charlie Yu and Bremer, {Ryan E.} and Joseph Chu and Haas, {Thomas S.} and Liang Cheng",
year = "2014",
doi = "10.5858/arpa.2013-0221-OA",
language = "English",
volume = "138",
pages = "943--949",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "7",

}

TY - JOUR

T1 - A newly developed uroplakin ii antibody with increased sensitivity in urothelial carcinoma of the bladder

AU - Hoang, Laura L.

AU - Tacha, David E.

AU - Qi, Weimin

AU - Yu, Charlie

AU - Bremer, Ryan E.

AU - Chu, Joseph

AU - Haas, Thomas S.

AU - Cheng, Liang

PY - 2014

Y1 - 2014

N2 - Context.-Uroplakin II is a 15-kDa protein component of the urothelial plaques that enhance the permeability barrier and strength of the urothelium. Studies have shown uroplakin II messenger RNA to be expressed in bladder cancer tissues and peripheral blood of patients with urothelial carcinoma. Little is known about the protein expression of uroplakin II in urothelial carcinoma, possibly because of the absence of a commercially available uroplakin II antibody. Pathologists have used the uroplakin III antibody (AU1) to identify tumors of urothelial origin; however, the use of AU1 is limited because of its poor sensitivity. Objectives.-To evaluate a newly developed mouse monoclonal uroplakin II antibody (BC21) in urothelial carcinoma and to compare it with previously developed mouse monoclonal uroplakin III (BC17 and AU1). Design.-Uroplakin II and III antibodies were optimized for staining using a horseradish peroxidase-polymer detection system and were visualized with 3,30-diaminobenzidine. Results.-BC21, BC17, and AU1 demonstrated sensitivities in urothelial carcinoma of the bladder of 79% (44 of 56), 55% (31 of 56) (P = 002), and 34% (19 of 56) (P < .001), respectively. Subsequently, the increased staining sensitivity and intensity of BC21, compared with BC17, was validated in a larger study (134 of 174; 77% and 94 of 174; 54%, respectively) (P < .001). BC21 was found to be highly specific when evaluated in various normal and neoplastic tissues, including prostatic and renal carcinomas. Conclusions.-The mouse monoclonal uroplakin II antibody (BC21) demonstrated superior sensitivity and specificity in urothelial carcinoma, compared with uroplakin III (BC17 and AU1), suggesting its advantages in the differential diagnosis of urothelial carcinoma and in the detection of tumors of unknown origin.

AB - Context.-Uroplakin II is a 15-kDa protein component of the urothelial plaques that enhance the permeability barrier and strength of the urothelium. Studies have shown uroplakin II messenger RNA to be expressed in bladder cancer tissues and peripheral blood of patients with urothelial carcinoma. Little is known about the protein expression of uroplakin II in urothelial carcinoma, possibly because of the absence of a commercially available uroplakin II antibody. Pathologists have used the uroplakin III antibody (AU1) to identify tumors of urothelial origin; however, the use of AU1 is limited because of its poor sensitivity. Objectives.-To evaluate a newly developed mouse monoclonal uroplakin II antibody (BC21) in urothelial carcinoma and to compare it with previously developed mouse monoclonal uroplakin III (BC17 and AU1). Design.-Uroplakin II and III antibodies were optimized for staining using a horseradish peroxidase-polymer detection system and were visualized with 3,30-diaminobenzidine. Results.-BC21, BC17, and AU1 demonstrated sensitivities in urothelial carcinoma of the bladder of 79% (44 of 56), 55% (31 of 56) (P = 002), and 34% (19 of 56) (P < .001), respectively. Subsequently, the increased staining sensitivity and intensity of BC21, compared with BC17, was validated in a larger study (134 of 174; 77% and 94 of 174; 54%, respectively) (P < .001). BC21 was found to be highly specific when evaluated in various normal and neoplastic tissues, including prostatic and renal carcinomas. Conclusions.-The mouse monoclonal uroplakin II antibody (BC21) demonstrated superior sensitivity and specificity in urothelial carcinoma, compared with uroplakin III (BC17 and AU1), suggesting its advantages in the differential diagnosis of urothelial carcinoma and in the detection of tumors of unknown origin.

UR - http://www.scopus.com/inward/record.url?scp=84904011306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904011306&partnerID=8YFLogxK

U2 - 10.5858/arpa.2013-0221-OA

DO - 10.5858/arpa.2013-0221-OA

M3 - Article

C2 - 24978921

AN - SCOPUS:84904011306

VL - 138

SP - 943

EP - 949

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 7

ER -